NUREXONE BIOLOGIC INC (NRX.CA) Stock Price, Forecast & Analysis
Canada - TSX-V:NRX - CA67059R1091 - Common Stock
NRX.CA Key Statistics, Chart & Performance
The current stock price of NRX.CA is 0.7 CAD. In the past month the price decreased by -5.41%. In the past year, price decreased by -6.67%.
NRX.CA Latest News, Press Relases and Analysis
NRX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 444.77M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 391.60M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 187.13M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 120.11M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 23.75 | 52.10M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.48M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 30.11M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 18.99M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 15.64M | ||
| MPH.CA | MEDICURE INC | N/A | 14.93M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.69M | ||
| TELO.CA | TELO GENOMICS CORP | N/A | 7.03M |
Related stock screener links
About NRX.CA
Company Profile
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a proprietary platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
Company Info
NUREXONE BIOLOGIC INC
Minus 1 Entry, Ground Floor Of Bldg B
Haifa ALBERTA IL
Employees: 12
Phone: 972524803034
NUREXONE BIOLOGIC INC / NRX.CA FAQ
What does NRX do?
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a proprietary platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
What is the current price of NRX stock?
The current stock price of NRX.CA is 0.7 CAD.
Does NRX stock pay dividends?
NRX.CA does not pay a dividend.
How is the ChartMill rating for NUREXONE BIOLOGIC INC?
NRX.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about NUREXONE BIOLOGIC INC (NRX.CA) stock?
9 analysts have analysed NRX.CA and the average price target is 3.12 CAD. This implies a price increase of 345.16% is expected in the next year compared to the current price of 0.7.
What is the Price/Earnings (PE) ratio of NUREXONE BIOLOGIC INC (NRX.CA)?
NUREXONE BIOLOGIC INC (NRX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
What is the ownership structure of NUREXONE BIOLOGIC INC (NRX.CA)?
You can find the ownership structure of NUREXONE BIOLOGIC INC (NRX.CA) on the Ownership tab.
NRX.CA Technical Analysis
NRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NRX.CA. Both the profitability and financial health of NRX.CA have multiple concerns.
NRX.CA Financial Highlights
Over the last trailing twelve months NRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS decreased by -10.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -220.67% | ||
| ROE | -412.53% | ||
| Debt/Equity | 0.06 |
NRX.CA Forecast & Estimates
9 analysts have analysed NRX.CA and the average price target is 3.12 CAD. This implies a price increase of 345.16% is expected in the next year compared to the current price of 0.7.